FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386089557> ?p ?o ?g. }

• W4386089557 abstract "Worldwide, opioid use causes more than 100,000 overdose deaths annually. Naloxone has proven efficacy in reversing opioid overdoses and is approved as an emergency antidote to opioid overdose. Take home naloxone (THN) programmes have been introduced to provide 'community members', who are likely to observe opioid overdoses, with naloxone kits and train them to recognise an overdose and administer naloxone. The acceptability and feasibility of THN programmes has been demonstrated, but the real-life effectiveness of naloxone administration by community members is not known. In recent years, the approval of several concentrated naloxone nasal-spray formulations (in addition to injectable formulations, eg.prenoxad) potentially increases acceptability and scope for wider provision. This study aims to determine the effectiveness of THN (all formulations) in real-world conditions.A European, multi-country, prospective cohort study, to assess the use of THN by community members to reverse opioid overdoses in a six-month, follow-up period. Participants provided with THN from participating harm reduction and drug treatment sites will be recruited to the study and followed-up for six months. We are particularly interested in the experiences of community members who have been provided with THN and have witnessed an opioid overdose. All participants who witness an opioid overdose during the six-month period (target approx. 600) will be asked to take part in a structured interview about this event. Of these, 60 will be invited to participate in a qualitative interview. A Post Authorisation Efficacy Study (PAES) for the concentrated nasal naloxone, Nyxoid, has been integrated into the study design.There are many challenges involved in evaluating the real-life effectiveness of THN. It is not possible to use a randomised trial design, recruitment of community members provided with THN will depend upon recruitment sites distributing THN kits, and the type of THN received by participants will depend on regulations and on local clinical and policy decision-makers. Following up this population, some of whom may be itinerant, over the 6-month study period will be challenging, but we plan to maintain contact with participants through regular text message reminders and staff contact.ClinicalTrials.gov Identifier: NCT05072249. Date of Registration: 8.10.2021." @default.
• W4386089557 created "2023-08-24" @default.
• W4386089557 creator A5012537308 @default.
• W4386089557 creator A5018265398 @default.
• W4386089557 creator A5022312633 @default.
• W4386089557 creator A5024073544 @default.
• W4386089557 creator A5028696190 @default.
• W4386089557 creator A5031220226 @default.
• W4386089557 creator A5032907796 @default.
• W4386089557 creator A5040315189 @default.
• W4386089557 creator A5042996845 @default.
• W4386089557 creator A5046465972 @default.
• W4386089557 creator A5046703130 @default.
• W4386089557 creator A5060812676 @default.
• W4386089557 creator A5063021701 @default.
• W4386089557 creator A5076648140 @default.
• W4386089557 creator A5078176478 @default.
• W4386089557 creator A5092678708 @default.
• W4386089557 date "2023-08-24" @default.
• W4386089557 modified "2023-10-01" @default.
• W4386089557 title "A study protocol for a European, mixed methods, prospective, cohort study of the effectiveness of naloxone administration by community members, in reversing opioid overdose: NalPORS" @default.
• W4386089557 cites W1602761126 @default.
• W4386089557 cites W1984650467 @default.
• W4386089557 cites W2120952399 @default.
• W4386089557 cites W2139852527 @default.
• W4386089557 cites W2160243203 @default.
• W4386089557 cites W2202322071 @default.
• W4386089557 cites W2269979437 @default.
• W4386089557 cites W2292896704 @default.
• W4386089557 cites W2331803526 @default.
• W4386089557 cites W2346610964 @default.
• W4386089557 cites W2580429140 @default.
• W4386089557 cites W2583366328 @default.
• W4386089557 cites W2619968007 @default.
• W4386089557 cites W2768998640 @default.
• W4386089557 cites W2966156386 @default.
• W4386089557 cites W67968104 @default.
• W4386089557 doi "https://doi.org/10.1186/s12889-023-16445-6" @default.
• W4386089557 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37612698" @default.
• W4386089557 hasPublicationYear "2023" @default.
• W4386089557 type Work @default.
• W4386089557 citedByCount "0" @default.
• W4386089557 crossrefType "journal-article" @default.
• W4386089557 hasAuthorship W4386089557A5012537308 @default.
• W4386089557 hasAuthorship W4386089557A5018265398 @default.
• W4386089557 hasAuthorship W4386089557A5022312633 @default.
• W4386089557 hasAuthorship W4386089557A5024073544 @default.
• W4386089557 hasAuthorship W4386089557A5028696190 @default.
• W4386089557 hasAuthorship W4386089557A5031220226 @default.
• W4386089557 hasAuthorship W4386089557A5032907796 @default.
• W4386089557 hasAuthorship W4386089557A5040315189 @default.
• W4386089557 hasAuthorship W4386089557A5042996845 @default.
• W4386089557 hasAuthorship W4386089557A5046465972 @default.
• W4386089557 hasAuthorship W4386089557A5046703130 @default.
• W4386089557 hasAuthorship W4386089557A5060812676 @default.
• W4386089557 hasAuthorship W4386089557A5063021701 @default.
• W4386089557 hasAuthorship W4386089557A5076648140 @default.
• W4386089557 hasAuthorship W4386089557A5078176478 @default.
• W4386089557 hasAuthorship W4386089557A5092678708 @default.
• W4386089557 hasBestOaLocation W43860895571 @default.
• W4386089557 hasConcept C118552586 @default.
• W4386089557 hasConcept C126322002 @default.
• W4386089557 hasConcept C138816342 @default.
• W4386089557 hasConcept C159110408 @default.
• W4386089557 hasConcept C170493617 @default.
• W4386089557 hasConcept C194828623 @default.
• W4386089557 hasConcept C2775962371 @default.
• W4386089557 hasConcept C2776315796 @default.
• W4386089557 hasConcept C2778750930 @default.
• W4386089557 hasConcept C2778903686 @default.
• W4386089557 hasConcept C2779148768 @default.
• W4386089557 hasConcept C2780035454 @default.
• W4386089557 hasConcept C2781063702 @default.
• W4386089557 hasConcept C3017944768 @default.
• W4386089557 hasConcept C529928208 @default.
• W4386089557 hasConcept C71924100 @default.
• W4386089557 hasConceptScore W4386089557C118552586 @default.
• W4386089557 hasConceptScore W4386089557C126322002 @default.
• W4386089557 hasConceptScore W4386089557C138816342 @default.
• W4386089557 hasConceptScore W4386089557C159110408 @default.
• W4386089557 hasConceptScore W4386089557C170493617 @default.
• W4386089557 hasConceptScore W4386089557C194828623 @default.
• W4386089557 hasConceptScore W4386089557C2775962371 @default.
• W4386089557 hasConceptScore W4386089557C2776315796 @default.
• W4386089557 hasConceptScore W4386089557C2778750930 @default.
• W4386089557 hasConceptScore W4386089557C2778903686 @default.
• W4386089557 hasConceptScore W4386089557C2779148768 @default.
• W4386089557 hasConceptScore W4386089557C2780035454 @default.
• W4386089557 hasConceptScore W4386089557C2781063702 @default.
• W4386089557 hasConceptScore W4386089557C3017944768 @default.
• W4386089557 hasConceptScore W4386089557C529928208 @default.
• W4386089557 hasConceptScore W4386089557C71924100 @default.
• W4386089557 hasFunder F4320333641 @default.
• W4386089557 hasIssue "1" @default.
• W4386089557 hasLocation W43860895571 @default.
• W4386089557 hasLocation W43860895572 @default.
• W4386089557 hasOpenAccess W4386089557 @default.
• W4386089557 hasPrimaryLocation W43860895571 @default.
• W4386089557 hasRelatedWork W1907988016 @default.
• W4386089557 hasRelatedWork W2160563165 @default.

• next